Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.
Wall Street likes the company's promising pipeline ... this weight-loss drug stock could more than 3x over the next 12 ...
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback